NeutroSpec Pulled From The Market
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA "reconsidered" the risk/benefit balance for Mallinckrodt/Palatin Technologies' appendicitis imaging agent, which has been associated with cardiopulmonary events.